Federal prosecutors in Manhattan unsealed an indictment on June 6, 2026, charging Jianqing Li, also known as "JQ," with two counts of securities fraud [1]. Li, a Manhattan-based investment analyst at an asset manager focused on biomedical and healthcare investments, allegedly used material, nonpublic information misappropriated from his employer to trade in stocks and options, generating more than $350,000 in illicit profits [1].
The charges arise under federal securities fraud statutes, which prohibit trading on confidential information obtained in breach of a duty of trust or confidence. Prosecutors allege Li accessed deal-sensitive information through his position at the firm and then placed trades ahead of market-moving announcements, a pattern consistent with the misappropriation theory of insider trading liability [1]. U.S. Attorney Jay Clayton for the Southern District of New York announced the charges, with investigative credit attributed to the FBI New York Field Office, whose assistant director-in-charge, James C. Barnacle Jr., participated in the announcement [1].
The indictment was filed under seal before being publicly released on June 6. Each securities fraud count carries a statutory maximum of 20 years in prison, and a conviction would also expose Li to civil disgorgement and financial penalties under parallel Securities and Exchange Commission enforcement authority, though no parallel SEC civil action has been publicly announced as of the unsealing [1]. Li's employer has not been named or publicly identified as a subject of the investigation.
The case reflects the continued focus of the SDNY and the FBI on insider trading at investment firms with access to pre-announcement corporate intelligence, particularly in the biomedical sector, where acquisition activity and clinical trial results regularly generate significant, market-sensitive information. Clayton, who served as SEC chairman from 2017 to 2021 before being appointed U.S. Attorney, has signaled that securities enforcement remains a priority for the office [1].
Next steps will depend on Li's arraignment and the entry of a plea. Defense counsel has not been identified in publicly available records. The case is at an early procedural stage, with discovery, potential motion practice, and trial scheduling all pending.